CompletedPhase 4

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Mexico18 participantsStarted 2014-05

Plain-language summary

The purpose of this study is to evaluate the therapeutic efficacy of interferon alfa 2b and topical mitomycin C in patients with diagnosis of conjunctival-corneal intraepithelial neoplasia.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with clinical diagnosis of corneal and conjunctival intraepithelial neoplasia (CIN) with no history of ocular neoplasia Exclusion Criteria: * Patients who did not agree to participate in the study. * Patients with corneal abrasion * Patients who have the diagnosis of CIN, but are pregnant

What they're measuring

Therapeutic effect - 100% resolution- with interferon alfa-2b and mitomycin C in patients diagnosed with primary conjunctival-corneal intraepithelial neoplasia

Timeframe: One month to one year

Trial details

NCT IDNCT02199327

SponsorCoordinación de Investigación en Salud, Mexico

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2016-12-16

View on ClinicalTrials.gov More Conjunctival Intraepithelial Neoplasia trials